Daxor Secures Patent for Remote Blood Volume Monitoring System
Event summary
- Daxor Corporation received U.S. Patent No. 12,635,917 B2 for a remote blood volume monitor on June 2, 2026.
- The patent covers systems for continuous, remote tracking of blood volume using wearable sensors like smartwatches.
- The technology integrates with Daxor’s blood volume analysis algorithms to provide real-time updates without repeated tracer injections.
- The system offers predictive alerts for conditions like heart failure, syncope, anemia, and polycythemia.
The big picture
Daxor’s patent represents a strategic shift in blood volume management, moving from episodic hospital-based procedures to continuous, remote monitoring. This aligns with broader trends in telehealth and wearable health technology, potentially reducing hospital readmissions and improving outcomes for chronic conditions. The integration with other patient monitoring systems could further enhance its value proposition in the healthcare market.
What we're watching
- Market Adoption
- How quickly healthcare providers will integrate this remote monitoring technology into existing workflows.
- Competitive Response
- Whether competitors will develop similar remote monitoring solutions, potentially intensifying market competition.
- Regulatory Compliance
- The pace at which Daxor can navigate regulatory approvals for expanded use cases of the patented technology.